Popular
ROIV · Medicine & biotech · U.K.

Roivant

Starts and runs small drug companies, such as Immunovant.

Company Health

25
/100
Weak
A quick check of the business from its yearly reports (2023–2026). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $3629 of every $100 in sales.
Is it growing?
0 of 25 · Poor
Sales shrank about 36% a year over the last 3 years.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $9184 of every $100 in sales.

Who owns it

1 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Roivant’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales fell from $23.8 million in the year to Mar 2021 to $8.26 million in the year to Mar 2026, and it made a profit in 1 of the 6 years.
FY2026
Sales
$8.26 million
Loss
$300 million

Spare cash each year

It spent more cash than it brought in every year: $759 million more in the year to Mar 2026.
FY2026
Cash shortfall
$759 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of Mar 2026 it owned $5.71 billion, including $1.42 billion in cash, and owed $416 million.

Key facts

From its yearly report for the year to Mar 2026.
Sales
$8.26 million
Loss
$300 million
Cash shortfall
$759 million
Cash in the bank
$1.42 billion
Everything it owes
$416 million
Year ends
March
Money shown in
U.S. dollars
Latest yearly report
10-K, filed May 20, 2026
Figures from Roivant’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy